Epner D E, White P, Krasnoff M, Khanduja S, Kimball K T, Knaus W A
Johns Hopkins Oncology Center, Baltimore, MD, USA.
J Investig Med. 1996 Jun;44(5):254-60.
Patients with hematologic malignancy who develop respiratory failure generally have a very poor prognosis. A few such patients, however, enjoy long-term survival. The objective of this study was to identify clinical characteristics of patients with hematologic malignancy and respiratory failure that are predictive of outcome.
We performed a retrospective chart review of all patients who required mechanical ventilation for acute respiratory failure while on the leukemia or bone marrow transplantation units at the Johns Hopkins Oncology Center between January 1985 and October 1991 (n = 157).
Overall hospital mortality was 83%. Major organ system dysfunction, as measured by the acute physiology score (APS) of the APACHE III prognostic system, was significantly (P < 0.05) related to hospital mortality. Three disease-specific clinical characteristics were predictive of mortality: 1) stage beyond first complete remission, 2) duration of neutropenia greater than 30 days, and 3) treatment with bone marrow transplantation, especially if HLA-mismatched. None of the 15 (10%) patients with neutropenia greater than 30 days or the four patients who underwent HLA-mismatched transplantation survived to discharge. Age was also a significant predictor of hospital mortality.
Overall outcome of patients with hematologic malignancy and acute respiratory failure is poor. A larger prospective study will be required to confirm the relative value of disease-specific variables identified in this study when combined with established predictive variables. In the future, it may be possible to develop a predictive instrument that is specifically tailored for patients with hematologic malignancy who develop respiratory failure.
发生呼吸衰竭的血液系统恶性肿瘤患者通常预后很差。然而,少数此类患者可长期存活。本研究的目的是确定血液系统恶性肿瘤合并呼吸衰竭患者中可预测预后的临床特征。
我们对1985年1月至1991年10月期间在约翰霍普金斯肿瘤中心白血病或骨髓移植病房因急性呼吸衰竭需要机械通气的所有患者进行了回顾性病历审查(n = 157)。
总体医院死亡率为83%。根据APACHE III预后系统的急性生理学评分(APS)衡量的主要器官系统功能障碍与医院死亡率显著相关(P < 0.05)。有三个疾病特异性临床特征可预测死亡率:1)首次完全缓解后的分期,2)中性粒细胞减少持续时间超过30天,3)接受骨髓移植治疗,尤其是HLA配型不合的情况。15名(10%)中性粒细胞减少持续时间超过30天的患者或4名接受HLA配型不合移植的患者均无存活出院者。年龄也是医院死亡率的重要预测因素。
血液系统恶性肿瘤合并急性呼吸衰竭患者的总体预后较差。需要进行更大规模的前瞻性研究,以证实本研究中确定的疾病特异性变量与既定预测变量相结合时的相对价值。未来,有可能开发一种专门针对发生呼吸衰竭的血液系统恶性肿瘤患者的预测工具。